Details of the Drug
General Information of Drug (ID: DMMVWSY)
| Drug Name |
CK-101
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 530.6 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.3 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 9 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Non-small-cell lung cancer | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 2C25.Y | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


